BiotechTube
Home/Sulfateq/Rob Henning
RH

Rob Henning

Chair, Scientific Advisory Board

Sulfateq

Therapeutic Areas

NeurodegenerationChronic Kidney DiseaseCardiovascular DiseasePulmonary Disease

Sulfateq Pipeline

DrugIndicationPhase
SUL-238Parkinson's Disease (Mitochondrial Dysfunction)Phase 2
SUL-150Diabetic Kidney Disease, COPD, Heart Failure, NeurodegenerationPreclinical
SUL-151Diabetic Kidney Disease, COPD, Heart Failure, NeurodegenerationPreclinical

Leadership Team at Sulfateq

KV
Kees van der Graaf
Chief Executive Officer
DS
Daniël Swart
Chief Operating Officer
GK
Guido Krenning
Chief Scientific Officer
HB
Hans Bruining
Chief Financial Officer
View full Sulfateq profile